Compugen Ltd.
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Compugen Ltd. is a clinical-stage cancer immunotherapy company that specializes in the discovery and development of novel therapeutics. The company utilizes its proprietary computational discovery platform, Unigen™, which integrates artificial intelligence and machine learning (AI/ML) with deep scientific knowledge to identify novel drug targets. Compugen's primary focus is on developing first-in-class therapeutic antibodies and optimizing their combinations to treat cancer patients who are unresponsive or refractory to existing immunotherapies. A key area of its research involves the PVRIG pathway, a target the company discovered to enhance patient responses. Its pipeline consists of several therapeutic candidates currently being evaluated in multiple clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-10 15:00 |
Foreign Filer Report
Reports Third Quarter 2025 Results
|
English | 516.5 KB | ||
| 2025-11-10 15:00 |
Foreign Filer Report
Reports Third Quarter 2025 Results
|
English | 36.4 KB | ||
| 2025-11-04 15:00 |
Regulatory News Service
Compugen to Participate in Stifel 2025 Healthcare Conference
|
English | 149.5 KB | ||
| 2025-11-04 15:00 |
Foreign Filer Report
Compugen to Participate in Stifel 2025 Healthcare Conference
|
English | 36.4 KB | ||
| 2025-10-27 14:00 |
Report Publication Announcement
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
|
English | 130.8 KB | ||
| 2025-10-27 14:00 |
Foreign Filer Report
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
|
English | 36.4 KB | ||
| 2025-10-14 16:00 |
Foreign Filer Report
Immediate Report
|
English | 522.6 KB | ||
| 2025-10-14 16:00 |
Foreign Filer Report
Immediate Report
|
English | 36.6 KB | ||
| 2025-10-13 16:00 |
Regulatory News Service
Other Report or Announcement
|
English | 159.5 KB | ||
| 2025-10-13 16:00 |
Foreign Filer Report
Other Report or Announcement
|
English | 36.5 KB | ||
| 2025-10-06 16:00 |
Regulatory News Service
Other Report or Announcement
|
English | 159.9 KB | ||
| 2025-10-06 16:00 |
Foreign Filer Report
Other Report or Announcement
|
English | 36.4 KB | ||
| 2025-09-17 16:00 |
Foreign Filer Report
RESULTS OF A MEETING HELD ON AUGUEST 6, 2025
|
English | 106.4 KB | ||
| 2025-09-17 16:00 |
Foreign Filer Report
RESULTS OF A MEETING HELD ON AUGUEST 6, 2025
|
English | 36.3 KB | ||
| 2025-09-08 16:00 |
Regulatory News Service
to Present Research at the Single Cell Genomics 2025 Conference
|
English | 94.0 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
